Abstract: The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-CD4 CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.

Abstract: The invention generally relates to products for use in the treatment and/or prevention of Pulmonary Arterial Hypertension (PAH). More specifically, the invention relates to translocator protein (TSPO) binding members which treat or prevent pulmonary endothelial cell dysfunction, and the use of such TSPO binding members for use in the treatment and/or prevention of PAH [FIG. 1].

Abstract: The invention relates to ZIP12 antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of hypoxia-related diseases, such as pulmonary hypertension and cancer.

Abstract: The present invention related to identification of therapeutic agents of the treatment, diagnosis, and prevention of pulmonary hypertension.

Abstract: The present invention provides a novel partial-pressure mass spectrometer calibration device, which is mainly composed of a fine adjustment valve, a piston pressure gauge, a sample preparation chamber, a plurality of high-purity gas cylinders, a capacitive film vacuum gauge, a first-stage sample inlet chamber, a second-stage sample inlet chamber, sampling chambers, a small hole, a calibration chamber, a separation gauge and air pumping systems, wherein the sample preparation chamber is connected with the piston pressure gauge and the capacitive film vacuum gauge; the sample preparation chamber is also connected with the plurality of high-purity gas cylinders which are connected in parallel via the fine adjustment valve; a plurality of sampling chambers with different volumes are connected in parallel between the sample preparation chamber and the first-stage sample inlet chamber; a plurality of sampling chambers with different volumes are connected in parallel between the first-stage sample inlet chamber and

Abstract: A polypropylene composition, a preparation method thereof, and a film or a sheet prepared from the polypropylene composition and use thereof. The composition includes 45 parts to 75 parts of a polypropylene, 10 parts to 35 parts of an elastomer, 5 parts to 20 parts of a polyethylene, 0.1 parts to 0.5 parts of an antioxidant, and 0.1 parts to 0.5 parts of a lubricant. A half peak width of a crystallization peak of the polypropylene is 5° C. to 10° C., and a peak temperature of the crystallization peak of the polypropylene is 105° C. to 115° C. The polypropylene composition has a good tenacity, especially a?30° C. low-temperature impact performance. The film or the sheet prepared from the composition and applied to automotive interior parts, can enable the external accessories not only to be less likely to generate sharp fragments while being strongly impacted, but also to have a matte characteristic.

Abstract: The present invention related to identification of therapeutic agents of the treatment, diagnosis, and prevention of pulmonary hypertension.

Abstract: A polypropylene composition, a preparation method thereof, and a film or a sheet prepared from the polypropylene composition and use thereof. The composition includes 45 parts to 75 parts of a polypropylene, 10 parts to 35 parts of an elastomer, 5 parts to 20 parts of a polyethylene, 0.1 parts to 0.5 parts of an antioxidant, and 0.1 parts to 0.5 parts of a lubricant. A half peak width of a crystallization peak of the polypropylene is 5° C. to 10° C., and a peak temperature of the crystallization peak of the polypropylene is 105° C. to 115° C. The polypropylene composition has a good tenacity, especially a ?30° C. low-temperature impact performance. The film or the sheet prepared from the composition and applied to automotive interior parts, can enable the external accessories not only to be less likely to generate sharp fragments while being strongly impacted, to guarantee the safety of people, but also to have a matte characteristic.

Abstract: The present invention relates to identification of therapeutic agents for the treatment, diagnosis, and prevention of pulmonary hypertension.

Abstract: A trim component for a vehicle interior configured to provide an opening for deployment of an airbag is disclosed. The component may comprise a weakened substrate and insert to direct deployment of the airbag. The insert may comprise a film formed from a polypropylene composition and may be secured between an airbag chute and the substrate. The film may be bonded to the substrate. The chute may be welded to the film and the substrate. The polypropylene composition may comprise polypropylene, an elastomer and polyethylene. The chute may be formed from a thermoplastic polyolefin material. A weakened portion of the insert and a weakened portion of the substrate may be formed concurrently. Thermoplastic polypropylene material may be injected into a mold at a temperature to form the substrate and melt the film in order to bond the film to the substrate.

Abstract: A Zr-based amorphous alloy has the following formula: ZraCubAlcNidTieMf. a, b, c, d, e, and f of the formula are corresponding atomic percents with 50?a?55, 25?b?30, 15?c?24, 0.1?d?9, 0.1?e?5, 0.1?f?5, and a+b+c+d+e+f?100. M is selected from one or more of the following group consisting of Sc, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, and mixtures thereof.

Abstract: Provided are a process for preparing an N ortho acyl substituted nitrogen-containing heterocyclic compound and an aminal iron (II) complex thereof, and the use of the complexes obtained by the process in an olefin oligomerization catalyst. The N ortho acyl substituted nitrogen-containing heterocyclic compound in the present invention is for example 2-acyl-1,10-phenanthroline or 2,6-diacetyl pyridine as shown in formula b, and the N ortho acyl substituted nitrogen-containing heterocyclic compound in the present invention is produced by a reaction of a precursor thereof in a substituted or unsubstituted nitrobenzene. Preferably the precursor shown in formula I in the present invention is produced by 1,10-phenanthroline reacting with trialkyl aluminum, or a halogenoalkyl aluminum RnAIXm, or a substituted or unsubstituted benzyl lithium Ph?CH2Li, followed by hydrolysis.

Abstract: Provided are a process for preparing an N ortho acyl substituted nitrogen-containing heterocyclic compound and an aminal iron (II) complex thereof, and the use of the complexes obtained by the process in an olefin oligomerization catalyst. The N ortho acyl substituted nitrogen-containing heterocyclic compound in the present invention is for example 2-acyl-1,10-phenanthroline or 2,6-diacetyl pyridine as shown in formula b, and the N ortho acyl substituted nitrogen-containing heterocyclic compound in the present invention is produced by a reaction of a precursor thereof in a substituted or unsubstituted nitrobenzene. Preferably the precursor shown in formula I in the present invention is produced by 1,10-phenanthroline reacting with trialkyl aluminum, or a halogenoalkyl aluminum RnAlXm, or a substituted or unsubstituted benzyl lithium 2Li, followed by hydrolysis.

Abstract: The present invention provides a catalyst composition for the ethylene oligomerization, which comprises 2-imino-1,10-phenanthroline coordinated iron (II), cobalt (II) or nickel (II) chloride as main catalyst and triethylaluminum as cocatalyst. The present invention also provides a process for oligomerization of ethylene is provided, wherein a catalyst composition comprising 2-imino-1,10-phenanthroline coordinated iron (II), cobalt (II) or nickel (II) chloride as main catalyst and triethylaluminum as cocatalyst is used, and the molar ratio of aluminum in the cocatalyst to central metal in the main catalyst ranges from 30 to less than 200. According to the present invention, another process for oligomerization of ethylene is also provided, wherein a catalyst composition comprising 2-imino-1,10-phenanthroline coordinated iron (II), cobalt (II) or nickel (II) chloride as main catalyst and triethylaluminum as cocatalyst is used, and the temperature of ethylene oligomerization ranges from ?10 to 19° C.

Abstract: The invention provides a process for making a particulate mesoporous material. A solution comprising a surfactant and a base is combined with a hydrolysable precursor without agitating said solution. The resulting mixture is then allowed to stand without externally applied agitation for sufficient time for hydrolysis of the precursor to form the particulate mesoporous material.